LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials
Ann Rheum Dis. 2025:S0003-496700071-8. DOI: 10.1016/j.ard.2025.01.016. Epub ahead of print
Morand et al. conducted a post-hoc analysis of the phase III TULIP-1 and TULIP-2 trials and their long-term extension, including 369 patients with moderate to severe SLE, to evaluate the long-term impact of anifrolumab on attainment of LLDAS and DORIS-defined remission. The results demonstrated that anifrolumab significantly improved the likelihood, speed, and duration of LLDAS and DORIS remission versus placebo over 4 years, with benefits sustained throughout the treatment period.
This study utilised data from patients who received anifrolumab 300 mg or placebo every 4 weeks across the 52-week TULIP trials and subsequent 3-year LTE. Analyses included logistic regression, Cox models, and analysis of covariance to assess treatment group differences in proportion attaining LLDAS/DORIS, time to first attainment, and cumulative time in target states. The findings support the role of anifrolumab in achieving durable, clinically meaningful treat-to-target outcomes in SLE management.
Keywords:
